PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35243658-9	2022	Following milrinone therapy, median BNP levels decreased significantly (882 (286-3768) to 631 (278-1378) pg/ml, p = .017) with a significant reduction in the number of patients with New York Heart Association (NYHA) Class III and IV (p = .012, 0.013) and an increase in number of patients on GDMT.	Milrinone	10-19	natriuretic peptide B	Homo sapiens	36-39	
35083882-12	2022	CONCLUSIONS: In this small-scale study of ambulatory advanced HF patients, we observed improvements in right ventricular systolic function, maximal O2 consumption, and BNP after switching from milrinone to levosimendan based IIT.	Milrinone	193-202	natriuretic peptide B	Homo sapiens	168-171